NCT06212154View on ClinicalTrials.gov

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 20, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Autoimmune Hemolytic AnemiaCD19 CAR-T Cell Infusion
Interventions
BIOLOGICAL

ThisCART19A

Participants will receive ThisCART19A cell infusion after preconditioning, and they need to be closely monitored for 28 days following CAR-T cell infusion.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
collaborator

Suzhou Fundamenta Therapeutics

UNKNOWN

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER